Menu
Our team studies the mechanisms underlying chronic liver disease progression to cirrhosis and its complications, with an emphasis on the identification of prognosis markers and therapeutic targets for steatotic liver diseases. Our research program focuses on the identification of immunometabolic targets and biomarkers of liver and systemic inflammation.
We study the mechanisms underlying monocyte/macrophage reprogramming and the impact on fatty liver disease progression to fibrosis, and on liver regeneration. The role of adaptive immune cells (Th17) and non-conventional T lymphocytes, in particular mucosal-associated invariant T (MAIT) cells, in the control of inflammation at sequential steps of steatotic liver diseases progression and regression.
Novel biomarkers and clinical studies evaluating new therapeutic strategies in metabolic dysfunction-associated fatty liver disease (MAFLD), cirrhosis, transplantation and acute-on-chronic liver failure (ACLF), a syndrome we characterized and in which systemic inflammation is a major trigger.
Scientific Advisory Board
Member (2021–present)
Centre de Recherches sur l’Inflammation, Université Paris Cité, UMR 1149 Inserm, France
Inflammatory and Stress Responses in Chronic Liver Diseases Group, Group Leader
International Recognition Award, European Association for the Study of the Liver (EASL)
2022
European Foundation for the Study of
Chronic Liver Failure
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain
© European Foundation for the Study of Chronic Liver Failure 2024
